Author: Liu Fangbing Misra Preeti Lunsford Elaine Vannah Joanne Liu Yuxia Lenkinski Robert Frangioni John
Publisher: Springer Publishing Company
ISSN: 0167-6806
Source: Breast Cancer Research and Treatment, Vol.122, Iss.1, 2010-07, pp. : 87-94
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
The development of novel diagnostic agents for the detection of breast cancer microcalcifications requires a reliable animal model. Based on previous work from our group, we hypothesized that a single systemic injection of recombinant bone morphogenetic protein-2 (rBMP-2) could be used to create such a model. The cDNA encoding mature human BMP-2 was expressed in BL21(DE3) bacteria, purified to homogeneity, and refolded as a dimer. Bioactivity was confirmed using a C2C12 alkaline phosphatase assay. rBMP-2 was radiolabeled with 99mTc, and its biodistribution and clearance were quantified after both intravenous (IV) and intraperitoneal (IP) injection. Fischer 344 rats bearing syngeneic R3230 breast tumors received a single intraperitoneal injection of rBMP-2 at a specified dose. Tumor microcalcification was quantified over time using micro–single photon emission computed tomography (SPECT) and microcomputed tomography (CT). rBMP-2 could be expressed in
Related content
Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 17, Iss. 7, 2017-06 ,pp. :